U.S. Breast Conserving Surgery Market Size, Share, Trends, Industry Analysis Report By Product Type (Lumpectomy Devices, Radiofrequency Ablation Devices), By Surgery Type, By End User, By Technology – Market Forecast, 2025–2034
Description
The U.S. breast conserving surgery market size is expected to reach USD 1,428.00 million by 2034, according to a new study by Polaris Market Research. The report “U.S. Breast Conserving Surgery Market Share, Size, Trends, Industry Analysis Report By Product Type (Lumpectomy Devices, Radiofrequency Ablation Devices), By Surgery Type, By End User, By Technology; Market Forecast, 2025–2034” gives a detailed insight into current market dynamics and provides analysis on future market growth.
Breast conserving surgery (BCS), also known as lumpectomy or partial mastectomy, is used to remove cancerous tissue from the breast while preserving as much healthy tissue as possible. This approach is typically recommended for early-stage breast cancer patients where the tumor is relatively small compared to breast size. BCS is almost always followed by radiation therapy to eliminate any remaining cancer cells and reduce recurrence risk. The benefits of BCS include maintaining breast appearance, shorter recovery time, and less psychological impact compared to mastectomy. However, not all patients are candidates for BCS. Various factors such as tumor size, location, and multicentric disease influence eligibility.
In the U.S., breast conserving surgery (BCS) is a widely utilized treatment for early-stage breast cancer, supported by guidelines from organizations such as the National Comprehensive Cancer Network (NCCN). The U.S. healthcare system is emphasizing multidisciplinary care, combining BCS with radiation therapy in oncology based on individual risk factors. Advances in imaging and surgical techniques, such as oncoplastic surgery, have improved cosmetic outcomes, further increasing BCS adoption.
U.S. Breast Conserving Surgery Market Report Highlights
In terms of product type, the lumpectomy devices segment accounted for a major U.S. breast conserving surgery market revenue share in 2024 due to their widespread adoption as the standard surgical approach for early-stage breast cancer.
The radiofrequency ablation devices segment, based on product type, is projected to grow at a robust pace in the coming years, driven by its minimally invasive nature and increasing use among patients who are ineligible for traditional surgery.
Based on surgery type, the tumor lumpectomy segment held the largest U.S. breast conserving surgery market revenue share in 2024 due to its widespread acceptance as a first-line treatment for early-stage breast cancer.
In terms of end user, the hospitals segment dominated the revenue share in 2024 due to their advanced infrastructure, multidisciplinary care teams, and access to comprehensive diagnostic and therapeutic resources.
Based on technology, the traditional surgical techniques segment accounted for a major market share in 2024 due to their long-standing use, widespread surgeon familiarity, and proven clinical outcomes.
The image-guided surgery segment, in terms of technology, is projected to grow at a rapid pace during the assessment period owing to its ability to offer precision and real-time visualization in achieving clear margins and minimizing re-excisions.
A few key market players include Argon Medical Devices; CairnSurgical Inc.; Hologic, Inc; Innoblative Designs; KUBTEC; Lumicell Inc; Mammotome (Danaher); Merit Medical Systems; Perimeter Medical Imaging AI; and Stryker.
Polaris Market Research has segmented the U.S. breast conserving surgery market report on the basis of product type, surgery type, end user, and technology:
By Product Type Outlook (Revenue, USD Million, 2020–2034)
Lumpectomy Devices
Radiofrequency Ablation Devices
Cryoablation Devices
Microwave Ablation Devices
Others
By Surgery Type Outlook (Revenue, USD Million, 2020–2034)
Segmental Mastectomy
Quadrantectomy
Tumor Lumpectomy
By End User Outlook (Revenue, USD Million, 2020–2034)
Hospitals
Ambulatory Surgical Centers (ASCs)
Specialty Clinics
Cancer Research Institutes
By Technology Outlook (Revenue, USD Million, 2020–2034)
Traditional Surgical Techniques
Image-guided Surgery
Robotic-assisted Surgery
Minimally Invasive Techniques
Breast conserving surgery (BCS), also known as lumpectomy or partial mastectomy, is used to remove cancerous tissue from the breast while preserving as much healthy tissue as possible. This approach is typically recommended for early-stage breast cancer patients where the tumor is relatively small compared to breast size. BCS is almost always followed by radiation therapy to eliminate any remaining cancer cells and reduce recurrence risk. The benefits of BCS include maintaining breast appearance, shorter recovery time, and less psychological impact compared to mastectomy. However, not all patients are candidates for BCS. Various factors such as tumor size, location, and multicentric disease influence eligibility.
In the U.S., breast conserving surgery (BCS) is a widely utilized treatment for early-stage breast cancer, supported by guidelines from organizations such as the National Comprehensive Cancer Network (NCCN). The U.S. healthcare system is emphasizing multidisciplinary care, combining BCS with radiation therapy in oncology based on individual risk factors. Advances in imaging and surgical techniques, such as oncoplastic surgery, have improved cosmetic outcomes, further increasing BCS adoption.
U.S. Breast Conserving Surgery Market Report Highlights
In terms of product type, the lumpectomy devices segment accounted for a major U.S. breast conserving surgery market revenue share in 2024 due to their widespread adoption as the standard surgical approach for early-stage breast cancer.
The radiofrequency ablation devices segment, based on product type, is projected to grow at a robust pace in the coming years, driven by its minimally invasive nature and increasing use among patients who are ineligible for traditional surgery.
Based on surgery type, the tumor lumpectomy segment held the largest U.S. breast conserving surgery market revenue share in 2024 due to its widespread acceptance as a first-line treatment for early-stage breast cancer.
In terms of end user, the hospitals segment dominated the revenue share in 2024 due to their advanced infrastructure, multidisciplinary care teams, and access to comprehensive diagnostic and therapeutic resources.
Based on technology, the traditional surgical techniques segment accounted for a major market share in 2024 due to their long-standing use, widespread surgeon familiarity, and proven clinical outcomes.
The image-guided surgery segment, in terms of technology, is projected to grow at a rapid pace during the assessment period owing to its ability to offer precision and real-time visualization in achieving clear margins and minimizing re-excisions.
A few key market players include Argon Medical Devices; CairnSurgical Inc.; Hologic, Inc; Innoblative Designs; KUBTEC; Lumicell Inc; Mammotome (Danaher); Merit Medical Systems; Perimeter Medical Imaging AI; and Stryker.
Polaris Market Research has segmented the U.S. breast conserving surgery market report on the basis of product type, surgery type, end user, and technology:
By Product Type Outlook (Revenue, USD Million, 2020–2034)
Lumpectomy Devices
Radiofrequency Ablation Devices
Cryoablation Devices
Microwave Ablation Devices
Others
By Surgery Type Outlook (Revenue, USD Million, 2020–2034)
Segmental Mastectomy
Quadrantectomy
Tumor Lumpectomy
By End User Outlook (Revenue, USD Million, 2020–2034)
Hospitals
Ambulatory Surgical Centers (ASCs)
Specialty Clinics
Cancer Research Institutes
By Technology Outlook (Revenue, USD Million, 2020–2034)
Traditional Surgical Techniques
Image-guided Surgery
Robotic-assisted Surgery
Minimally Invasive Techniques
Table of Contents
129 Pages
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
